NCT04120506View on ClinicalTrials.gov

Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 10, 2016

Primary Completion Date

January 20, 2017

Study Completion Date

January 1, 2022

Conditions
Gaucher Disease, Type 1
Interventions
DRUG

VPRIV

Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease

Sponsors

Collaborators (1)

Shire
All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Shaare Zedek Medical Center

OTHER